Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Lepore starts Aug. 18 at Air Products, which has 23,000 employees spread across 50 countries and ranks 347th in the Fortune ...

Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Nationwide employment law firm Jackson Lewis PC has added Kaha Kvachatadze as a principal in its White Plains office. He ...

Severance plans subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) must satisfy certain compliance requirements, ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

A truck arrives to the loading bays at the US company Pfizer manufacturing plant in Puurs, Belgium.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

In July 2025, Bristol-Myers Squibb announced a study is to assess the safety and efficacy of nivolumab combined with ...